Toxoplasmosis, an overview with emphasis on ocular involvement

Ocular Immunology and Inflammation

Volumn 10, Issue 1, 2002, Pages 1-26

  Klaren, Vincent N A ^a   Kijlstra, Aize ^b,c  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Immune response; Infection; Pathogenesis; Toxoplasmosis; Uveitis

Indexed keywords

CLINICAL FEATURE; EYE DISEASE; HUMAN; INFECTION; NONHUMAN; PARASITE; SHORT SURVEY; TOXOPLASMOSIS;

ACUTE DISEASE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; CHRONIC DISEASE; EYE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; NETHERLANDS; PREVALENCE; TOXOPLASMA; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; TOXOPLASMOSIS, OCULAR;

EID: 0036941286     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.10.1.1.10330     Document Type: Short Survey

References (190)

1. Frenkel JK, Ruiz A, Chinchilla M. Soil survival of toxoplasma oocysts in Kansas and Costa Rica. Am J Trop Med Hyg. 1975;24:439-443.
2. Inskeep W, Gardiner CH, Harris RK, Dubey JP, Goldston RT. Toxoplasmosis in Atlantic bottle-nosed dolphins (Tursiops truncatus). J Wildlife Dis. 1990;26:377-382.
3. Migaki G, Sawa TR, Dubey JP. Fatal disseminated toxoplasmosis in a spinner dolphin (Stenella longirostris). Vet Pathol. 1990;27:463-464.
4. Holshuh HJ, Sherrod AE, Taylor CR, Andrews BF, Howard EB. Toxoplasmosis in a feral northern fur seal. J Am Vet Med Assoc. 1985;187:1229-1230.
5. Cole RA, Lindsay DS, Howe DK, Roderick CL, Dubey JP, Thomas NJ, Baeten LA. Biological and molecular characterizations of Toxoplasma gondii strains obtained from southern sea otters (Enhydra lutris nereis). J Parasitol. 2000;86:526-530.
6. Figueroa DR. [Risk of transmission of infectious diseases by transfusion]. Ginecol Obstet Mex. 1998;66:277-283.
7. Mayes JT, O'Connor BJ, Avery R, Castellani W, Carey W. Transmission of Toxoplasma gondii infection by liver transplantation. Clin Infect Dis. 1995;21:511-515.
8. Michaels MG, Wald ER, Fricker FJ, del Nido PJ, Armitage J. Toxoplasmosis in pediatric recipients of heart transplants. Clin Infect Dis. 1992;14:847-851.
9. Renoult E, Biava MF, Hulin C, Frimat L, Hestin D, Kessler M. Transmission of toxoplasmosis by renal transplant: A report of four cases. Transplant Proc. 1996;28:181-183.
10. Mayes JT, O'Connor BJ, Avery R, Castellani W, Carey W. Transmission of Toxoplasma gondii infection by liver transplantation. Clin Infect Dis. 1995;21:511-515.
11. Ejmocka-Ambroziak A, Kozoowska-Boszko B, Lao M, Marianowski L. [Toxoplasmosis as a risk factor in pregnant women after renal transplantation]. Wiad Lek. 1994;47:700-701.
12. Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, Foulon W, Semprini AE, Dunn DT. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. Br Med J. 2000;321:142-147.
13. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: From animals to humans. Int J Parasitol. 2000;30:1217-1258.
14. Dubey JP. Toxoplasma gondii. In: Baron S, editor. Medical Microbiology. Galveston, Texas: The University of Texas Medical Branch, 1996.
15. Frenkel JK. Pathophysiology of toxoplasmosis. Parasitol Today. 1988;4:273-278.
16. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. Food-related illness and death in the United States. Emerg Infect Dis. 1999;5:607-625.
17. Dubey JP, Frenkel JK. Feline toxoplasmosis from acutely infected mice and the development of Toxoplasma cysts. J Protozool. 1976;23:537-546.
18. Hoff RL, Dubey JP, Behbehani AM, Frenkel JK. Toxoplasma gondii cysts in cell culture: New biologic evidence. J Parasitol. 1977;63:1121-1124.
19. Mitchell WG. Neurocysticercosis and acquired cerebral toxoplasmosis in children. Semin Pediatr Neurol. 1999;6:267-277.
20. Calore EE, Minkovski R, Khoury Z, Seguro AC, Perez Calore NM, Cavaliere MJ. Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii. J Rheumatol. 2000;27:1556-1559.
21. Leak D, Meghji M. Toxoplasmic infection in cardiac disease. Am J Cardiol. 1979;43:841-849.
22. Jacobs L. The resistance of the encysted form of Toxoplasma gondii. J Parasitol. 1960;46:11-21.
23. Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev. 1998;11:569-588.
24. Luft BJ, Brooks RG, Conley FK, McCabe RE, Remington JS. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. J Am Med Assoc. 1984;252:913-917.
25. Navia BA, Petito CK, Gold JW, Cho ES, Jordan BD, Price RW. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: Clinical and neuropathological findings in 27 patients. Ann Neurol. 1986;19:224-238.
26. Suzuki Y, Conley FK, Remington JS. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol. 1989;143:2045-2050.
27. Holland GN, Engstrom REJ, Glasgow BJ, Berger BB, Daniels SA, Sidikaro Y, Harmon JA, Fischer DH, Boyer DS, Rao NA. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653-667.
28. Flegr J, Hrdy I. Influence of chronic toxoplasmosis on some human personality factors. Folia Parasitol (Praha). 1994;41:122-126.
29. Flegr J, Hrda S, Tachezy J. The role of psychological factors in questionnaire-based studies on routes of human toxoplasmosis transmission. Cent Eur J Public Health. 1998;6:45-50.
30. Zimmer C. Evolution. Parasites make scaredy-rats foolhardy. Science. 2000;289:525-527.
31. Flegr J, Havlicek J. Changes in the personality profile of young women with latent toxoplasmosis. Folia Parasitol (Praha). 1999;46:22-28.
32. Webster JP, Brunton CF, Macdonald DW. Effect of Toxoplasma gondii upon neophobic behaviour in wild brown rats, Rattus norvegicus. Parasitology. 1994;109(Pt1):37-43.
33. Webster JP. The effect of Toxoplasma gondii and other parasites on activity levels in wild and hybrid Rattus norvegicus. Parasitology. 1994;109(Pt5):583-589.
34. Berdoy M, Webster JP, Macdonald DW. Fatal attraction in rats infected with Toxoplasma gondii. Proc R Soc Lond B Biol Sci. 2000;267:1591-1594.
35. Flegr J, Zitkova S, Kodym P, Frynta D. Induction of changes in human behaviour by the parasitic protozoan Toxoplasma gondii. Parasitology. 1996;113(Pt1):49-54.
36. Flegr J, Kodym P, Tolarova V. Correlation of duration of latent Toxoplasma gondii infection with personality changes in women. Biol Psychol. 2000;53:57-68.
37. Yolken RH, Bachmann S, Rouslanova I, Lillehoj E, Ford G, Torrey EF, Schroeder J. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001;32:842-844.
38. Dubey JP. Tissue cyst tropism in Toxoplasma gondii: A comparison of tissue cyst formation in organs of cats and rodents fed oocysts. Parasitology. 1997;115:15-20.
39. Pavesio CE, Chiappino ML, Setzer PY, Nichols BA. Toxoplasma gondii: Differentiation and death of bradyzoites. Parasitol Res. 1992;78:1-9.
40. Dubey JP. Bradyzoite-induced murine toxoplasmosis: Stage conversion, pathogenesis, and tissue cyst formation in mice fed bradyzoites of different strains of Toxoplasma gondii. J Eukaryot Microbiol. 1997;44:592-602.
41. Dubey JP, Speer CA, Shen SK, Kwok OC, Blixt JA. Oocyst-induced murine toxoplasmosis: Life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts. J Parasitol. 1997;83:870-882.
42. Weiss LM, Kim K. The development and biology of bradyzoites of Toxoplasma gondii. Front Biosci. 2000;5:D391-D405.
43. Denkers EY. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes Infect. 1999;1:699-708.
44. Gonzalez-Morales T, Bacallo-Gallestey J, Garcia-Santana CA, Molina-Garcia JR. [Prevalence of Toxoplasma gondii antibodies in a population of pregnant women in Cuba]. Gac Med Mex. 1995;131:499-503.
45. Guimaraes AC, Kawarabayashi M, Borges MM, Tolezano JE, Andrade HF, Jr. Regional variation in toxoplasmosis seronegativity in the Sao Paulo metropolitan region. Rev Inst Med Trop Sao Paulo. 1993;35:479-483.
46. Lelong B, Rahelimino B, Candolfi E, Ravelojaona BJ, Villard O, Rasamindrakotroka AJ, Kien T. Prevalence of toxoplasmosis in a population of pregnant women in Antananarivo (Madagascar). Bull Soc Pathol Exot. 1995;88:46-49.
47. Jenum PA, Kapperud G, Stray-Pedersen B, Melby KK, Eskild A, Eng J. Prevalence of Toxoplasma gondii specific immunoglobulin G antibodies among pregnant women in Norway. Epidemiol Infect. 1998;120:87-92.
48. Lappalainen M, Koskela P, Hedman K, Teramo K, Ammala P, Hiilesmaa V, Koskiniemi M. Incidence of primary toxoplasma infections during pregnancy in southern Finland: A prospective cohort study. Scand J Infect Dis. 1992;24:97-104.
49. Van der Veen J, Polak MF. Prevalence of toxoplasma antibodies according to age with comments on the risk of prenatal infection. J Hyg. 1980;85:165-174.
50. Kortbeek LM. Changes in seroprevalence ofToxoplasma in the Netherlands. In: Proceedings of the Spring Meeting BSP/NVP; 1999 April11-14; Coventry, UK.
51. Davies PR, Morrow WE, Deen J, Gamble HR, Patton S. Seroprevalence of Toxoplasma gondii and Trichinella spiralis in finishing swine raised in different production systems in North Carolina, USA. Prev Vet Med. 1998;36:67-76.
52. Van Knapen F, Kremers AF, Franchimont JH, Narucka U. Prevalence of antibodies to Toxoplasma gondii in cattle and swine in The Netherlands: towards an integrated control of livestock production. Vet Q. 1995;17:87-91.
53. Gilbert RE, Dunn DT, Lightman S, Murray PI, Pavesio CE, Gormley PD, Masters J, Parker SP, Stanford MR. Incidence of symptomatic toxoplasma eye disease: Aetiology and public health implications. Epidemiol Infect. 1999;123:283-289.
54. Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, Grumet FC, McLeod R. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol. 1999;29:1351-1358.
55. Suzuki Y, Wong SY, Grumet FC, Fessel J, Montoya JG, Zolopa AR, Portmore A, Schumacher-Perdreau F, Schrappe M, Koppen S, Ruf B, Brown BW, Remington JS. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis. 1996;173:265-268.
56. Meenken C, Rothova A, de Waal LP, van der Horst AR, Mesman BJ, Kijlstra A. HLA typing in congenital toxoplasmosis. Br J Ophthalmol. 1995;79:494-497.
57. Windeck T, Gross U. Toxoplasma gondii strain-specific transcript levels of SAG1 and their association with virulence. Parasitol Res. 1996;82:715-719.
58. Grimwood J, Smith JE. Toxoplasma gondii: The role of a 30-kDa surface protein in host cell invasion. Exp Parasitol. 1992;74:106-111.
59. Parmley SF, Gross U, Sucharczuk A, Windeck T, Sgarlato GD, Remington, JS. Two alleles of the gene encoding surface antigen P22 in 25 strains of Toxoplasma gondii. J Parasitol. 1994;80:293-301.
60. Howe DK, Sibley LD. Toxoplasma gondii comprises three clonal lineages: Correlation of parasite genotype with human disease. J Infect Dis. 1995;172:1561-1566.
61. Howe DK, Honore S, Derouin F, Sibley LD. Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J Clin Microbiol. 1997;35:1411-1414.
62. Rizzo LV, Vallochi AL, Schleisinger D, Martins MC, Silveira C, Belfort R, Jr. In Brazil, Toxoplasma gondii strains causing ocular lesions in asymptomatic patients are different from those in symptomatic patients. In: Proceedings of the ARVO, Clinical Uveitis II; 2001; Fort Lauderdale, Florida, USA.
63. Mack D, McLeod R, Stark B. Characterization of ribonuclease P from Toxoplasma gondii. J Eukaryot Microbiol. 1996;41:13S-Oct.
64. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66:767-774.
65. Lebech M, Larsen SO, Petersen E. Prevalence, incidence and geographical distribution of Toxoplasma gondii antibodies in pregnant women in Denmark. Scand J Infect Dis. 1993;25:751-756.
66. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, Abroms I, Pasternack MS, Hoff R, Eaton RB. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994;330:1858-1863.
67. Koppe JG, Loewer-Sieger DH, Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1:254-256.
68. Lappalainen M, Koskiniemi M, Hiilesmaa V, Ammala P, Teramo K, Koskela P, Lebech M, Raivio KO, Hedman K. Outcome of children after maternal primaryToxoplasma infection during pregnancy with emphasis on avidity of specific IgG. The Study Group. Pediatr Infect Dis J. 1995;14:354-361.
69. Lebech M, Andersen O, Christensen NC, Hertel J, Nielsen HE, Peitersen B, Rechnitzer C, Larsen SO, Norgaard-Pedersen B, Petersen E. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. Lancet. 1999;353:1834-1837.
70. Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol. 1973;57:1-17.
71. Holland GN, O'Connor GR, Belfort R, Jr., Remington JS. Toxoplasmosis. In: Pepose J, Holland G, Wilhelmus K, editors. Ocular infection and immunity. St. Louis: Mosby, 1996;1183-1223.
72. Nussenblatt RB, Belfort R, Jr. Ocular toxoplasmosis. An old disease revisited. J Am Med Assoc. 1994;271:304-307.
73. Glasner PD, Silveira C, Kruszon-Moran D, Martins MC, Burnier M, Jr., Silveira S, Camargo ME, Nussenblatt RB, Kaslow RA, Belfort R, Jr. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136-144.
74. Holland GN. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J Ophthalmol. 1999;128:502-505.
75. Holland GN, Muccioli C, Silveira C, Weisz JM, Belfort R, Jr., O'Connor GR. Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol. 1999;128:413-420.
76. Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis. 1996;23:277-282.
77. Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? Br J Ophthalmol. 2000;84:224-226.
78. Akstein RB, Wilson LA, Teutsch SM. Acquired toxoplasmosis. Ophthalmology. 1982;89:1299-1302.
79. Masur H, Jones TC, Lempert JA, Cherubini TD. Outbreak of toxoplasmosis in a family and documentation of acquired retinochoroiditis. Am J Med. 1978; 64:396-402.
80. Sacks JJ, Roberto RR, Brooks NF. Toxoplasmosis infection associated with raw goat's milk. J Am Med Assoc. 1982;248:1728-1732.
81. Burnett AJ, Shortt SG, Isaac-Renton J, King A, Werker D, Bowie WR. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology. 1998;105:1032-1037.
82. Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, Marion SA. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team [see comments]. Lancet. 1997;350:173-177.
83. Bell A, Gill R, Isaac-Renton J, King A, Martinez L, Roscoe D, Werker D, Eng S, Johnstone T, Stanwick R. Outbreak of toxoplasmosis associated with municipal drinking water - British Columbia. The British Columbia Toxoplasmosis Team. Can Commun Dis Rep. 1995;21:161-163.
84. Aramini JJ, Stephen C, Dubey JP, Engelstoft C, Schwantje H, Ribble CS. Potential contamination of drinking water with Toxoplasma gondii oocysts. Epidemiol Infect. 1999;122:305-315.
85. Aramini JJ, Stephen C, Dubey JP. Toxoplasma gondii in Vancouver Island cougars (Felis concolor vancouverensis): Serology and oocyst shedding. J Parasitol. 1998;84:438-440.
86. Mullens A. 'I think we have a problem in Victoria': MDs respond quickly to toxoplasmosis outbreak in BC. Can Med Assoc J. 1996;154:1721-1724.
87. Ronday MJ, Luyendijk L, Baarsma GS, Bollemeijer JG, Van der Lelij A, Rothova A. Presumed acquired ocular toxoplasmosis. Arch Ophthalmol. 1995;113:1524-1529.
88. McMenamin PG, Dutton GN, Hay J, Cameron S. The ultrastructural pathology of congenital murine toxoplasmic retinochoroiditis. Part I. The localization and morphology of Toxoplasma cysts in the retina. Exp Eye Res. 1986;43:529-543.
89. Davidson MG, Lappin MR, English RV, Tompkins MB. A feline model of ocular toxoplasmosis. Invest Ophthalmol Vis Sci. 1993;34:3653-3660.
90. Bosch-Driessen EH, Berendschot TTJM, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: Clinical features and prognosis of 154 patients. In: Bosch-Driessen EH. Ocular Toxoplasmosis. New Insights in Diagnosis, Clinical Features and Therapy (dissertation). Utrecht, The Netherlands: Utrecht University, 2001.
91. Kijlstra A, Luyendijk L, Baarsma GS, Rothova A, Schweitzer CM, Timmerman Z, de Vries J, Breebaart AC. Aqueous humor analysis as a diagnostic tool in toxoplasma uveitis. Int Ophthalmol. 1989;13:383-386.
92. De Boer JH, Luyendijk L, Rothova A, Kijlstra A. Analysis of ocular fluids for local antibody production in uveitis. Br J Ophthalmol. 1995;79:610-616.
93. Brezin AP, Eqwuagu CE, Silveira C, Thulliez P, Martins MC, Mahdi RM, Belfort R, Jr., Nussenblatt RB. Analysis of aqueous humor in ocular toxoplasmosis. N Engl J Med. 1991;324:699.
94. Bou G, Figueroa MS, Marti-Belda P, Navas E, Guerrero A. Value of PCR for detection of Toxoplasma gondii in aqueous humor and blood samples from immunocompetent patients with ocular toxoplasmosis. J Clin Microbiol. 1999;37:3465-3468.
95. De Boer JH, Verhagen C, Bruinenberg M, Rothova A, de Jong PT, Baarsma GS, Van der Lelij A, Ooyman FM, Bollemeijer JG, Derhaag PJ, Kijlstra A. Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol. 1996;121:650-658.
96. Danise A, Cinque P, Vergani S, Candino M, Racca S, Debona A, Novati R, Castagna A, Lazzarin A. Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:1100-1106.
97. Verbraak FD, Galema M, van den Horn GH, Bruinenberg M, Luyendijk L, Danner SA, Kijlstra A. Serological and polymerase chain reaction-based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. AIDS. 1996;10:1091-1099.
98. Miller D, Davis J, Rosa R, Diaz M, Perez E. Utility of tissue culture for detection of Toxoplasma gondii in vitreous humor of patients diagnosed with toxoplasmic retinochoroiditis. J Clin Microbiol. 2000;38:3840-3842.
99. Rothova A, Buitenhuis HJ, Meenken C, Baarsma GS, Boen-Tan TN, de Jon, PT, Schweitzer CM, Timmerman Z, de Vries J, Zaal MJ, et al. Therapy of ocular toxoplasmosis. Int Ophthalmol. 1989;13:415-419.
100. Smith RE, Nozik RA. Toxoplasmic retinochoroiditis. In: Smith RE, Nozik RA, editors. Uveitis, a Clinical Approach to Diagnosis and Management. Baltimore, MD: Williams & Wilkins, 1989;128-134.
101. Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148-153.
102. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991;164:170-171.
103. Araujo FG, Huskinson J, Remington JS. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991;35:293-299.
104. Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992;36:326-330.
105. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int J Exp Pathol. 1994;75:111-116.
106. Kohler S, Delwiche CF, Denny PW, Tilney LG, Webster P, Wilson RJ, Palmer JD, Roos DS. A plastid of probable green algal origin in Apicomplexan parasites. Science. 1997;275:1485-1489.
107. Soldati D. The apicoplast as a potential therapeutic target in toxoplasma and other apicomplexan parasites. Parasitol Today. 1999;15:5-7.
108. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R. Evidence for the shikimate pathway in apicomplexan parasites. Nature. 1998;393:801-805.
109. Stokkermans TJ, Schwartzman JD, Keenan K, Morrissette NS, Tilney LG, Roos DS. Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides. Exp Parasitol. 1996;84:355-370.
110. Rothova A. Ocular involvement in toxoplasmosis [published erratum appears in Br J Ophthalmol. 1993;77(10):683]. Br J Ophthalmol. 1993;77:371-377.
111. Holland GN, O'Connor GR, Diaz RF, Minasi P, Wara WM. Ocular toxoplasmosis in immunosuppressed nonhuman primates. Invest Ophthalmol Vis Sci. 1988;29:835-842.
112. Nozik RA, O'Connor GR. Studies on experimental ocular toxoplasmosis in the rabbit. II. Attempts to stimulate recurrences by local trauma, epinephrine, and corticosteroids. Arch Ophthalmol. 1970;84:788-791.
113. Gazzinelli RT, Brezin A, Li Q, Nussenblatt RB, Chan CC. Toxoplasma gondii: Acquired ocular toxoplasmosis in the murine model, protective role of TNF-alpha and IFN-gamma. Exp Parasitol. 1994;78:217-229.
114. Derouin F, Lacroix C, Sumyuen MH, Romand S, Garin YJ. [Experimental models of toxoplasmosis. Pharmacological applications]. Parasite. 1995;2:243-256.
115. Hunter CA, Subauste CS, Remington JS. The role of cytokines in toxoplasmosis. Biotherapy. 1994;7:237-247.
116. Frenkel JK, Escajadillo A. Cyst rupture as a pathogenic mechanism of toxoplasmic encephalitis. Am J Trop Med Hyg. 1987;36:517-522.
117. Frenkel JK. Pathogenesis of toxoplasmosis with a consideration of cyst rupture in Besnoita infection. Surv Ophthalmol. 1961;6:799-825.
118. Dutton GN, McMenamin PG, Hay J, Cameron S. The ultrastructural pathology of congenital murine toxoplasmic retinochoroiditis. Part II. The morphology of the inflammatory changes. Exp Eye Res. 1986;43:545-560.
119. Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1996;122:309-324.
120. Engstrom RE, Jr., Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601-610.
121. Nussenblatt RB, Gery I. Experimental autoimmune uveitis and its relationship to clinical ocular inflammatory disease. J Autoimmun. 1996;9:575-585.
122. Wyler DJ, Blackman HJ, Lunde MN. Cellular hypersensitivity to toxoplasmal and retinal antigens in patients with toxoplasmal retinochoroiditis. Am J Trop Med Hyg. 1980;29:1181-1186.
123. Nussenblatt RB, Mittal KK, Fuhrman S, Sharma SD, Palestine AG. Lymphocyte proliferative responses of patients with ocular toxoplasmosis to parasite and retinal antigens. Am J Ophthalmol. 1989;107:632-641.
124. Hirose S, Tanaka T, Nussenblatt RB, Palestine AG, Wiggert B, Redmond TM, Chader GJ, Gery I. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects. Curr Eye Res. 1988;7:393-402.
125. Kijlstra A, Hoekzema R, Van der Lelij A, Doekes G, Rothova A. Humoral and cellular immune reactions against retinal antigens in clinical disease. Curr Eye Res. 1990; 9(Suppl):85-89.
126. Feron EJ, Klaren VN, Wierenga EA, Verjans GM, Kijlstra A. Characterization of Toxoplasma gondii-specific T cells recovered from vitreous fluid of patients with ocular toxoplasmosis. Invest Ophthalmol Vis Sci. 2001;42:3228-3232
127. Hay J, Lee WR, Dutton GN, Hutchison WM, Siim JC. Congenital toxoplasmic retinochoroiditis in a mouse model. Ann Trop Med Parasitol. 1984;78:109-116.
128. Dao A, Fortier B, Soete M, Plenat F, Dubremetz JF. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype. Int J Parasitol. 2001;31:63-65.
129. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: The major mediator of resistance against Toxoplasma gondii. Science. 1988;240:516-518.
130. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol. 1991;146:286-292.
131. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol. 1994;153:2533-2543.
132. Gazzinelli RT, Xu Y, Hieny S, Cheever A, Sher A. Simultaneous depletion of CD4+ and CD8+ T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol. 1992;149:175-180.
133. Gazzinelli RT, Eltoum I, Wynn TA, Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol. 1993;151:3672-3681.
134. Scharton-Kersten TM, Wynn TA, Denkers EY, Bala S, Grunvald E, Hieny S, Gazzinelli RT, Sher A. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immunol. 1996;157:4045-4054.
135. Daubener W, Remscheid C, Nockemann S, Pilz K, Seghrouchni S, Mackenzie C, Hadding U. Anti-parasitic effector mechanisms in human brain tumor cells: Role of interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol. 1996;26:487-492.
136. Halonen SK, Taylor GA, Weiss LM. Gamma interferon-induced inhibition of Toxoplasma gondii in astrocytes is mediated by IGTP. Infect Immun. 2001;69:5573-5576.
137. Gazzinelli RT, Wysocka M, Hieny S, Schartonkersten T, Cheever A, Kuhn, R, Muller W, Trinchieri G, Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol. 1996;157:798-805.
138. Bliss SK, Zhang Y, Denkers EY. Murine neutrophil stimulation by Toxoplasma gondii antigen drives high level production of IFN-gamma-independent IL-12. J Immunol. 1999;163:2081-2088.
139. Bliss SK, Marshall AJ, Zhang Y, Denkers EY. Human polymorphonuclear leukocytes produce IL-12, TNF-alpha, and the chemokines macrophage-inflammatory protein-1 alpha and -1 beta in response to Toxoplasma gondii antigens. J Immunol. 1999; 162:7369-7375.
140. Denkers EY, Gazzinelli RT, Martin D, Sher A. Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. J Exp Med. 1993;178:1465-1472.
141. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines mumig and crg-2 induced in protozoan and viral infections in response to ifn-gamma with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol. 1996;157:4511-4520.
142. Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD, Luster AD. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity. 2000;12:483-494.
143. Yap G, Pesin M, Sher A. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol. 2000;165:628-631.
144. Lindberg RE, Frenkel JK. Toxoplasmosis in nude mice. J Parasitol. 1977;63:219-221.
145. Schluter D, Lohler J, Deckert M, Hof H, Schwendemann G. Toxoplasma encephalitis of immunocompetent and nude mice: Immunohistochemical characterisation of Toxoplasma antigen, infiltrates and major histocompatibility complex gene products. J Neuroimmunol. 1991;31:185-198.
146. Suzuki Y, Kobayashi A. Presence of high concentrations of circulating Toxoplasma antigens during acute Toxoplasma infection in athymic nude mice. Infect Immun. 1987;55:1017-1018.
147. Buxton D. Experimental infection of athymic mice with Toxoplasma gondii. J Med Microbiol. 1980;13:307-311.
148. Jones TC, Hirsch JG. The interaction betweenToxoplasma gondii and mammalian cells. II. The absence of lysosomal fusion with phagocytic vacuoles containing living parasites. J Exp Med. 1972;136:1173-1194.
149. Cesbron-Delauw M-F. Dense-granule organelles of Toxoplasma gondii: Their role in the host-parasite relationship. Parasitol Today. 1994;10:293-296.
150. Yang TH, Aosai F, Norose K, Ueda M, Yano A. Differential regulation of HLA-DR expression and antigen presentation in Toxoplasma gondii-infected melanoma cells by interleukin 6 and interferon gamma. Microbiol Immunol. 1996; 40:443-449.
151. Luder CG, Lang T, Beuerle B, Gross U. Down-regulation of MHC class II molecules and inability to up-regulate class I molecules in murine macrophages after infection with Toxoplasma gondii. Clin Exp Immunol. 1998;112:308-316.
152. Bogdan C, Rollinghoff M. How do protozoan parasites survive inside macrophages? Parasitol Today. 1999;15:22-28.
153. Brown CR, McLeod R. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol. 1990;145:3438-3441.
154. Montoya JG, Lowe KE, Clayberger C, Moody D, Do D, Remington JS, Talib S, Subauste CS. Human CD4+ and CD8+ T lymphocytes are both cytotoxic to Toxoplasma gondii-infected cells. Infect Immun. 1996;64:176-181.
155. Purner MB, Berens RL, Nash PB, Vanlinden A, Ross E, Kruse C, Krug EC, Curiel TJ. CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans. Infect Immun. 1996;64:4330-4338.
156. Curiel TJ, Krug EC, Purner MB, Poignard P, Berens RL. Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells. J Immunol. 1993;151:2024-2031.
157. Denkers EY, Caspar P, Sher A. Toxoplasma gondii possesses a superantigen activity that selectively expands murine T cell receptor V beta 5-bearing CD8+ lymphocytes. J Exp Med. 1994;180:985-994.
158. Subauste CS, Fuh F, Malefyt RD, Remington JS. Alpha-beta T cell response to Toxoplasma gondii in previously unexposed individuals. J Immunol. 1998;160:3403-3411.
159. Purner MB, Berens RL, Tomavo S, Lecordier L, Cesbron-Delauw MF, Kotzin BL, Curiel TJ. Stimulation of human T lymphocytes obtained from Toxoplasma gondii-seronegative persons by proteins derived from T. gondii. J Infect Dis. 1998;177:746-753.
160. Vallochi AL, Yamamoto JH, Schleisinger D, Machado MA, Silveira C, Martins MC, Belfort R, Jr., Kalil J, Rizzo LV. Lack of evidence for superantigen activity of Toxoplasma gondii towards human T cells. Braz J Med Biol Res. 2001;34:1023-1031.
161. McLeod R, Mack DG. Secretory IgA specific for Toxoplasma gondii. J Immunol. 1986;136:2640-2643.
162. Chardes T, Bourguin I, Mevelec MN, Dubremetz JF, Bout D. Antibody responses toToxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens. Infect Immun. 1990;58:1240-1246.
163. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun. 2000;68:1026-1033.
164. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol. 2000;164:2629-2634.
165. Mack DG, McLeod R. Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro. J Clin Invest. 1992;90:2585-2592.
166. Meek B, Klaren VN, van Haeringen NJ, Kijlstra A, Peek R. IgA antibodies to Toxoplasma gondii in human tears. Invest Ophthalmol Vis Sci. 2000;41:2584-2590.
167. Naot Y, Guptill DR, Mullenax J, Remington JS. Characterization of Toxoplasma gondii antigens that react with human immunoglobulin M and immunoglobulin G antibodies. Infect Immun. 1983;41:331-338.
168. Erlich HA, Rodgers G, Vaillancourt P, Araujo FG, Remington JS. Identification of an antigen-specific immunoglobulin M antibody associated with acute Toxoplasma infection. Infect Immun. 1983;41:683-690.
169. Decoster A, Darcy F, Capron A. Recognition of Toxoplasma gondii excreted and secreted antigens by human sera from acquired and congenital toxoplasmosis: Identification of markers of acute and chronic infection. Clin Exp Immunol. 1988;73:376-382.
170. Kasper LH, Ware PL. Recognition and characterization of stage-specific oocyst/sporozoite antigens of Toxoplasma gondii by human antisera. J Clin Invest. 1985;75:1570-1577.
171. Makioka A, Suzuki Y, Kobayashi A. Recognition of tachyzoite and bradyzoite antigens of Toxoplasma gondii by infected hosts. Infect Immun. 1991;59:2763-2766.
172. Sharma SD, Mullenax J, Araujo FG, Erlich HA, Remington JS. Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol. 1983;131:977-983.
173. Tomavo S, Fortier B, Soete M, Ansel C, Camus D, Dubremetz JF. Characterization of bradyzoite-specific antigens of Toxoplasma gondii. Infect Immun. 1991;59:3750-3753.
174. Geissler S, Sokolowska-Kohler W, Bollmann R, Jungblut PR, Presber W. Toxoplasma gondii infection: Analysis of serological response by 2-DE immunoblotting. FEMS Immunol Med Microbiol. 1999;25:299-311.
175. Huskinson J, Thulliez P, Remington JS. Toxoplasma antigens recognized by human immunoglobulin A antibodies. J Clin Microbiol. 1990;28:2632-2636.
176. Potasman I, Araujo FG, Desmonts G, Remington JS. Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis. 1986;154:650-657.
177. Potasman I, Araujo FG, Remington JS. Toxoplasma antigens recognized by naturally occurring human antibodies. J Clin Microbiol. 1986;24:1050-1054.
178. Santoro F, Afchain D, Pierce R, Cesbron JY, Ovlaque G, Capron A. Serodiagnosis of toxoplasma infection using a purified parasite protein (P30). Clin Exp Immunol. 1985;62:262-269.
179. Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, Kasper LH. Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. J Immunol. 1993;150:3951-3964.
180. Desmonts G. Definitive serological diagnosis of ocular toxoplasmosis. Arch Ophthalmol. 1966;76:839-851.
181. Klaren VNA, Van Doornik CEM, Ongkosuwito JV, Feron EJ, Kijlstra A. Differences between intraocular and serum antibody responses in patients with ocular toxoplasmosis. Am J Ophthalmol. 1998;126:698-706.
182. Klaren VNA, Peek R. Evidence for a compartmentalized B cell response as characterized by IgG epitope specificity in human ocular toxoplasmosis. J Immunol. 2001;167:6263-6269.
183. Cousins SW, Trattler WB, Streilein JW. Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr Eye Res. 1991;10:287-297.
184. Streilein JW, Wilbanks GA, Cousins SW. Immunoregulatory mechanisms of the eye. J Neuroimmunol. 1992;39:185-200.
185. Granstein RD, Staszewski R, Knisely TL, Zeira E, Nazareno R, Latina M, Albert DM. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation [published erratum appears in J Immunol. 1991;146(10):3687]. J Immunol. 1990;144:3021-3027.
186. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11:1199-1206.
187. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol. 1994;153:1080-1086.
188. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege [see comments]. Science. 1995;270:1189-1192.
189. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34:3579-3584.
190. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18:357-370.